Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Brief: Immuron Plans Phase 2 Trial For Imm-529 Following FDA Review

Immuron Ltd  IMC.AX :
    * IMMURON PLANS PHASE 2 TRIAL FOR IMM-529 FOLLOWING FDA
REVIEW
    * IMMURON LTD - INVESTIGATIONAL NEW DRUG (IND) APPLICATION
FOR
IMM-529 PLANNED FOR 1H 2025
    * IMMURON - COMPLETES PRE-IND MEETING WITH FDA ON
DEVELOPMENT OF
IMM-529 AS PRODUCT TO SPECIFICALLY PREVENT OR TREAT
CLOSTRIDIOIDES DIFFICILE INFECTION

Source text for Eikon:  ID:n0001213900-24-075787 
Further company coverage:  IMC.AX

Recent news on Immuron

See all news